Compare ITRM & UG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRM | UG |
|---|---|---|
| Founded | 2015 | 1942 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 27.7M |
| IPO Year | 2018 | N/A |
| Metric | ITRM | UG |
|---|---|---|
| Price | $0.31 | $7.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 497.5K | 9.5K |
| Earning Date | 03-20-2026 | 03-20-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | $390,000.00 | ★ $10,060,322.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $193.01 | N/A |
| P/E Ratio | ★ N/A | $18.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.26 | $5.58 |
| 52 Week High | $1.62 | $11.54 |
| Indicator | ITRM | UG |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 67.53 |
| Support Level | $0.31 | $6.25 |
| Resistance Level | $0.37 | $7.70 |
| Average True Range (ATR) | 0.03 | 0.24 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 9.44 | 74.50 |
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.